Long-term outcome for immune suppression and immune related lymphoproliferative disorder: prospective data from the United Kingdom Children's Leukaemia and Cancer Group registry 1994–2004

References

• Swerdlow SH. Post-transplant lymphoproliferative disorders: a working classification. Curr Diagn Pathol 1997;4:28–35.
   Google Scholar
• Swerdlow SH. Classification of the posttransplant lymphoproliferative disorders: from the past to the present. Semin Diagn Pathol 1997;14: 2–7.
   PubMed Web of Science ®Google Scholar
• Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997;14:8–14.
   PubMed Web of Science ®Google Scholar
• Gross TG, Bucuvalas JC, Park JR, . Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 2005; 23:6481–6488.
   PubMed Web of Science ®Google Scholar
• Tsai DE, Hardy CL, Tomaszewski JE, . Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001;71: 1076–1088.
   PubMed Web of Science ®Google Scholar
• Hayashi RJ, Kraus MD, Patel AL, . Posttransplant lymphoproliferative disease in children: correlation of histology to clinical behavior. J Pediatr Hematol Oncol 2001;23:14–18.
   PubMed Web of Science ®Google Scholar
• Taj MM, Messahel B, Mycroft J, . Efficacy and tolerability of high-dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children. Br J Haematol 2008;140:191–196.
   PubMed Web of Science ®Google Scholar
• Ifthikharuddin JJ, Mieles LA, Rosenblatt JD, . CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab. Am J Hematol 2000;65:171–173.
   PubMed Web of Science ®Google Scholar
• Messahel B, Taj MM, Hobson R, . Single agent efficacy of rituximab in childhood immunosuppression related lymphoproliferative disease: a United Kingdom Children's Cancer Study Group (UKCCSG) retrospective review. Leuk Lymphoma 2006;47:2584–2589.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Habermann TM, Ristow KM, . Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma 2005;46:191–196.
   PubMed Web of Science ®Google Scholar
• Elstrom RL, Andreadis C, Aqui NA, . Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006;6:569–576.
   PubMed Web of Science ®Google Scholar
• Pinkerton CR, Hann I, Weston CL, . Immunodeficiency-related lymphoproliferative disorders: prospective data from the United Kingdom Children's Cancer Study Group Registry. Br J Haematol 2002;118:456–461.
   PubMed Web of Science ®Google Scholar
• Malatack JF, , Gartner JC JrUrbach AH, . Orthotopic liver transplantation, Epstein-Barr virus, cyclosporine, and lymphoproliferative disease: a growing concern. J Pediatr 1991;118:667–675.
   PubMed Web of Science ®Google Scholar
• Gerrard M, CCLG National guidelines for the management of Burkitt/Burkitt like lymphoma and B Large Non Hodgkins Lymphoma.2003. http//www.cclg.org.uk
   Google Scholar
• Stata Statistical Software: Release 10. College Station, TX: StataCorp; 2007.
   Google Scholar
• Maecker B, Jack T, Zimmermann M, . CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol 2007;25:4902–4908.
   PubMed Web of Science ®Google Scholar
• Choquet S, Leblond V, Herbrecht R, . Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006;107:3053–3057.
   PubMed Web of Science ®Google Scholar
• Maloney DG. Mechanism of action of rituximab. Anticancer Drugs 2001;12(Suppl. 2):S1–S4.
   Google Scholar
• Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 2001;7:709–723.
   PubMed Web of Science ®Google Scholar
• Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007;26:3629–3636.
   PubMed Web of Science ®Google Scholar
• Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003;14:520–535.
   PubMed Web of Science ®Google Scholar
• Orjuela M, Gross TG, Cheung YK, . A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res 2003;9:3945S–3952S.
   PubMed Web of Science ®Google Scholar
• Gross TG, Orjuela M, Hayashi RJ, . Preliminary results of low dose chemotherapy and rituximab for pediatric, refractory post transplant lymphoproliferative disease (PTLD) following solid organ transplantation (SOT): a Children's Oncology Group phase II study. Hematol Meet Rep 2009;3:74.
   Google Scholar
• Smets F, Vajro P, Cornu G, . Indications and results of chemotherapy in children with posttransplant lymphoproliferative disease after liver transplantation. Transplantation 2000;69:982–984.
   PubMed Web of Science ®Google Scholar
• Windebank K, Walwyn T, Kirk R, . Post cardiac transplantation lymphoproliferative disorder presenting as t(8;14) Burkitt leukaemia/lymphoma treated with low intensity chemotherapy and rituximab. Pediatr Blood Cancer 2009;53:392–396.
   PubMed Web of Science ®Google Scholar
• Webber SA, Naftel DC, Fricker FJ, . Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet 2006;367:233–239.
   PubMed Web of Science ®Google Scholar
• Manlhiot C, Pollock-Barziv SM, Holmes C, . Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients. J Heart Lung Transplant 2010;29:648–657.
   PubMed Web of Science ®Google Scholar
• Ocheni S, Kroeger N, Zabelina T, . EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant 2008;42:181–186.
   PubMed Web of Science ®Google Scholar
• Gerritsen EJ, Stam ED, Hermans J, . Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. Bone Marrow Transplant 1996;18:377–382.
   PubMed Web of Science ®Google Scholar
• Jeon TY, Kim JH, Eo H, . Posttransplantation lymphoproliferative disorder in children: manifestations in hematopoietic cell recipients in comparison with liver recipients. Radiology 2010;257:490–497.
   PubMed Web of Science ®Google Scholar
• Curtis RE, Travis LB, Rowlings PA, . Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999;94:2208–2216.
   PubMed Web of Science ®Google Scholar
• van Esser JW, van der HB, Meijer E, . Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001;98:972–978.
   PubMed Web of Science ®Google Scholar
• Wagner HJ, Cheng YC, Huls MH, . Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004;103:3979–3981.
   PubMed Web of Science ®Google Scholar
• Faraci M, Caviglia I, Morreale G, . Viral-load and B-lymphocyte monitoring of EBV reactivation after allogeneic hemopoietic SCT in children. Bone Marrow Transplant 2010;45:1052–1055.
   PubMed Web of Science ®Google Scholar
• Annels NE, Kalpoe JS, Bredius RG, . Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. Clin Infect Dis 2006;42:1743–1748.
   PubMed Web of Science ®Google Scholar
• Meij P, van Esser JW, Niesters HG, . Impaired recovery of Epstein-Barr virus (EBV)-specific CD8 + T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003;101:4290–4297.
   PubMed Web of Science ®Google Scholar
• Clave E, Agbalika F, Bajzik V, . Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation 2004;77:76–84.
   PubMed Web of Science ®Google Scholar
• van Esser JW, Niesters HG, van der HB, . Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002;99:4364–4369.
   PubMed Web of Science ®Google Scholar